Imatinib is commonly used in the clinic to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST); it is an inhibitor that targets BCR-ABL kinase, c-Kit receptor, and PDGFR. This evidence concerns the gene PDGFRB and gastrointestinal stromal tumor.